Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies
Open Access
- 17 September 2019
- journal article
- Published by Journal of Oncological Sciences (JOS) in Journal of Oncological Sciences
- Vol. 5 (3) , 96-99
Abstract
Aim: In this retrospective study, the efficacy of adjuvant chemotherapy and its contribution to prognosis were investigated in patients diagnosed with different subgroups of ovarian carcinoma at stages 1–3. Material and Method Epithelial ovarian carcinoma cases treated at Ankara Oncology Training and Research Hospital of Health Sciences University between January 2014 and May 2018 were retrospectively analyzed. Results: A total of 145 patients were diagnosed and treated for EOC during the study period. According to histopathological subgroups, serous EOC was the most common (84.8%), followed by endometrioid (6.6%), mucinous (4.8%) and clear cell types (3.8%). Local recurrence and distant recurrences were observed in 39 (43.8%) and 7 (7.9%) cases in the serous EOC group, respectively. The median follow-up was 39 months (10–217 months). Median survival was 91.4 months (58.9–123.9 months) in the whole group and 100.9 months in serous EOC. Median survival in mucinous EOC was 26.2 months, whereas median survival in endometrioid EOC and clear cell EOC were not reached. A statistically significant difference of survival was found between serous and mucinous types of tumors (p: 0.04. Conclusions: According to the results of this study examining the survival outcomes of epithelial ovarian cancer subtypes after chemotherapy, there was a statistically significant difference between the prognosis of different epithelial ovarian cancer cases after taxane and platinum-containing adjuvant chemotherapy. Mucinous type of tumors exhibited less overall survival compared to endometrioid and clear cell types which needs to be confirmed with prospective clinical trials.Keywords
This publication has 11 references indexed in Scilit:
- Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control studyJournal of Gynecologic Oncology, 2013
- Natural history and outcome of mucinous carcinoma of the ovaryAmerican Journal of Obstetrics and Gynecology, 2011
- Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesisPathology, 2011
- Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethalCancer, 2010
- Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum‐paclitaxel chemotherapyCancer, 2010
- Clinicopathological characteristics of mucinous adenocarcinoma of the ovaryGynecologic Oncology, 2009
- Combination chemotherapy of oxaliplatin and 5‐fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategyCancer Science, 2009
- Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective studyBMC Cancer, 2008
- Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancersGynecologic Oncology, 2008
- Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific TreatmentJournal of Clinical Oncology, 2004